A Phase III Randomized Trial for Patients with de novo AML using Bortezomib and Sorafenib for patients with High Allelic Ratio FLT3/ITD
What is the purpose of this trial?
To compare event free survival (EFS) and overall survival (OS) in patients with de novo acute myeloid leukemia (AML) without high allelic ratio FLT3/ITD+ mutations who are randomized to standard therapy versus bortezomib/standard combination therapy.
- 0 Years - 30 Years
- Children's Oncology Group (The)
- Last Updated:
- Study HIC#: